Stairs instead of elevators at the workplace decreases PCSK9 levels in a healthy population
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Stairs instead of elevators at the workplace decreases PCSK9 levels in a healthy population
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
Volume 45, Issue 10, Pages 1017-1024
Publisher
Wiley
Online
2015-06-17
DOI
10.1111/eci.12480
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Physical Activity Level on Biomarkers of Inflammation and Insulin Resistance Over 5 Years in Outpatients With Coronary Heart Disease (from the Heart and Soul Study)
- (2014) Jennifer L. Jarvie et al. AMERICAN JOURNAL OF CARDIOLOGY
- PCSK9 levels in abdominally obese men: Association with cardiometabolic risk profile and effects of a one-year lifestyle modification program
- (2014) Benoit J. Arsenault et al. ATHEROSCLEROSIS
- Proprotein Convertase Subtilisin Kexin Type 9 Promotes Intestinal Overproduction of Triglyceride-Rich Apolipoprotein B Lipoproteins Through Both Low-Density Lipoprotein Receptor–Dependent and –Independent Mechanisms
- (2014) Shirya Rashid et al. CIRCULATION
- The effect of insulin on circulating PCSK9 in postmenopausal obese women
- (2014) Zuhier Awan et al. CLINICAL BIOCHEMISTRY
- Mechanism of action of anti-hypercholesterolemia drugs and their resistance
- (2014) Vishvanath Tiwari et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Annexin A2 Reduces PCSK9 Protein Levels via a Translational Mechanism and Interacts with the M1 and M2 Domains of PCSK9
- (2014) Kévin Ly et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells
- (2013) Emile Levy et al. ATHEROSCLEROSIS
- 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
- (2013) Neil J. Stone et al. CIRCULATION
- 2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk
- (2013) Robert H. Eckel et al. CIRCULATION
- Diagnosis and treatment of familial hypercholesterolaemia
- (2013) G. Kees Hovingh et al. EUROPEAN HEART JOURNAL
- Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society
- (2013) B. G. Nordestgaard et al. EUROPEAN HEART JOURNAL
- The influence of regular walking at different times of day on blood lipids and inflammatory markers in sedentary patients with coronary artery disease
- (2013) Xiao-Qing Lian et al. PREVENTIVE MEDICINE
- Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia
- (2012) Frederick Raal et al. CIRCULATION
- Physical Activity and Inflammatory Markers Over 10 Years
- (2012) Mark Hamer et al. CIRCULATION
- Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients
- (2012) David Sullivan et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effects of AMG 145 on Low-Density Lipoprotein Cholesterol Levels
- (2012) Clapton S. Dias et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- PCSK9 Inhibition
- (2012) Robert A. Vogel JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study
- (2012) Michael J Koren et al. LANCET
- Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study
- (2012) Robert P Giugliano et al. LANCET
- Annexin A2 Is a Natural Extrahepatic Inhibitor of the PCSK9-Induced LDL Receptor Degradation
- (2012) Nabil G. Seidah et al. PLoS One
- Effect of the Mediterranean diet with and without weight loss on surrogate markers of cholesterol homeostasis in men with the metabolic syndrome
- (2011) Caroline Richard et al. BRITISH JOURNAL OF NUTRITION
- Novel Loss-of-Function PCSK9 Variant Is Associated with Low Plasma LDL Cholesterol in a French-Canadian Family and with Impaired Processing and Secretion in Cell Culture
- (2011) J. Mayne et al. CLINICAL CHEMISTRY
- ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
- (2011) et al. EUROPEAN HEART JOURNAL
- Stairs instead of elevators at workplace: cardioprotective effects of a pragmatic intervention
- (2010) Philippe Meyer et al. EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION
- Effects of aerobic and strength-based training on metabolic health indicators in older adults
- (2010) Raul A Martins et al. Lipids in Health and Disease
- EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries
- (2009) Kornelia Kotseva et al. EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION
- A catalogue of reporting guidelines for health research
- (2009) I. Simera et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- Annexin A2 Is a C-terminal PCSK9-binding Protein That Regulates Endogenous Low Density Lipoprotein Receptor Levels
- (2008) Gaétan Mayer et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started